{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:15Z","timestamp":1791378315577,"version":"4.3.2"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702660"],"award-info":[{"award-number":["81702660"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472651"],"award-info":[{"award-number":["81472651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY20H160016"],"award-info":[{"award-number":["LY20H160016"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer (OC) causes more deaths than any other gynecological cancer. Many cellular pathways have been elucidated to be associated with OC development and progression. Specifically, the insulin-like growth factor 1 receptor\/insulin receptor substrate 1 (IGF1R\/IRS1) pathway participates in OC development. Moreover, accumulating evidence has shown that microRNA deregulation contributes to tumor initiation and progression. Here, our study aimed to investigate the molecular functions and regulatory mechanisms of miR-150, specifically, in OC. We found that the expression of miR-150-5p\/3p and their precursor, mir-150, was downregulated in OC tissues; lower mir-150 levels were associated with poor OC patient outcomes. Ectopic mir-150 expression inhibited OC cell growth and metastasis in vitro and in vivo. Furthermore, both IRS1 and IGF1R were confirmed as direct targets of miR-150-5p\/3p, and the miR-150-IGF1R\/IRS1 axis exerted antitumor effects via the PI3K\/AKT\/mTOR pathway. Forkhead box protein 3 (FoxP3) positively regulated the expression of miR-150-5p\/3p by binding to the mir-150 promoter. In turn, the PI3K\/AKT\/mTOR pathway downregulated FoxP3 and miR-150-5p\/3p. Taken together, these findings indicate that a complex FoxP3-miR-150-IGF1R\/IRS1-PI3K\/AKT\/mTOR feedback loop regulates OC pathogenesis, providing a novel mechanism for miR-150 as a tumor suppressor miRNA in OC.<\/jats:p>","DOI":"10.1038\/s41419-021-03554-6","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:05:22Z","timestamp":1615784722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["FoxP3-miR-150-5p\/3p suppresses ovarian tumorigenesis via an IGF1R\/IRS1 pathway feedback loop"],"prefix":"10.1038","volume":"12","author":[{"given":"Qinkai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunzhu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesha","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-An","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-3437","authenticated-orcid":false,"given":"Jianing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8223-1667","authenticated-orcid":false,"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"3554_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"Cancer J. Clin."},{"key":"3554_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A. et al. Ovarian cancer statistics, 2018. Cancer J. Clin. 68, 284\u2013296 (2018).","journal-title":"Cancer J. Clin."},{"key":"3554_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"Cancer J. Clin."},{"key":"3554_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PTJr Kroeger","year":"2017","unstructured":"Kroeger, P. T. Jr. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26\u201334 (2017).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"3554_CR5","doi-asserted-by":"crossref","unstructured":"Rojas, V., Hirshfield, K. M., Ganesan, S. & Rodriguez-Rodriguez, L. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int. J. Mol. Sci. 17, 2113 (2016).","DOI":"10.3390\/ijms17122113"},{"key":"3554_CR6","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1002\/jcp.26289","volume":"233","author":"L Norouzi-Barough","year":"2018","unstructured":"Norouzi-Barough, L. et al. Molecular mechanisms of drug resistance in ovarian cancer. J. Cell. Physiol. 233, 4546\u20134562 (2018).","journal-title":"J. Cell. Physiol."},{"key":"3554_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctrv.2017.08.012","volume":"60","author":"JAL Liefers-Visser","year":"2017","unstructured":"Liefers-Visser, J. A. L., Meijering, R. A. M., Reyners, A. K. L., van der Zee, A. G. J. & de Jong, S. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat. Rev. 60, 90\u201399 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"3554_CR8","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.18632\/oncotarget.12123","volume":"8","author":"D Vishwamitra","year":"2017","unstructured":"Vishwamitra, D., George, S. K., Shi, P., Kaseb, A. O. & Amin, H. M. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget 8, 1814\u20131844 (2017).","journal-title":"Oncotarget"},{"key":"3554_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","volume":"2","author":"SK Denduluri","year":"2015","unstructured":"Denduluri, S. K. et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2, 13\u201325 (2015).","journal-title":"Genes Dis."},{"key":"3554_CR10","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","volume":"14","author":"MM Chitnis","year":"2008","unstructured":"Chitnis, M. M., Yuen, J. S., Protheroe, A. S., Pollak, M. & Macaulay, V. M. The type 1 insulin-like growth factor receptor pathway. Clin. Cancer Res. 14, 6364\u20136370 (2008).","journal-title":"Clin. Cancer Res."},{"key":"3554_CR11","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin, Z. C. & Landen, C. N. The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int. J. Mol. Sci. 14, 8213\u20138227 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"3554_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera, M. K., Tennekoon, K. H. & Samarakoon, S. R. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin. Cancer Biol. 59, 147\u2013160 (2019).","journal-title":"Semin. Cancer Biol."},{"key":"3554_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","volume":"137","author":"S Mabuchi","year":"2015","unstructured":"Mabuchi, S., Kuroda, H., Takahashi, R. & Sasano, T. The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol. Oncol. 137, 173\u2013179 (2015).","journal-title":"Gynecol. Oncol."},{"key":"3554_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0938-x","volume":"18","author":"P Laissue","year":"2019","unstructured":"Laissue, P. The forkhead-box family of transcription factors: key molecular players in colorectal cancer pathogenesis. Mol. Cancer 18, 5 (2019).","journal-title":"Mol. Cancer"},{"key":"3554_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","volume":"22","author":"JD Fontenot","year":"2005","unstructured":"Fontenot, J. D. et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329\u2013341 (2005).","journal-title":"Immunity"},{"key":"3554_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nri2061","volume":"7","author":"DJ Campbell","year":"2007","unstructured":"Campbell, D. J. & Ziegler, S. F. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat. Rev. Immunol. 7, 305\u2013310 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"3554_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-6-19","volume":"6","author":"V Karanikas","year":"2008","unstructured":"Karanikas, V. et al. Foxp3 expression in human cancer cells. J. Transl. Med. 6, 19 (2008).","journal-title":"J. Transl. Med."},{"key":"3554_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/jcp.24125","volume":"228","author":"T Triulzi","year":"2013","unstructured":"Triulzi, T., Tagliabue, E., Balsari, A. & Casalini, P. FOXP3 expression in tumor cells and implications for cancer progression. J. Cell. Physiol. 228, 30\u201335 (2013).","journal-title":"J. Cell. Physiol."},{"key":"3554_CR19","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/onc.2010.174","volume":"29","author":"F Martin","year":"2010","unstructured":"Martin, F., Ladoire, S., Mignot, G., Apetoh, L. & Ghiringhelli, F. Human FOXP3 and cancer. Oncogene 29, 4121\u20134129 (2010).","journal-title":"Oncogene"},{"key":"3554_CR20","first-page":"170","volume":"1871","author":"H Jia","year":"2019","unstructured":"Jia, H. et al. The expression of FOXP3 and its role in human cancers. Biochim. Biophys. Acta 1871, 170\u2013178 (2019).","journal-title":"Biochim. Biophys. Acta"},{"key":"3554_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.molonc.2011.03.001","volume":"5","author":"M Redpath","year":"2011","unstructured":"Redpath, M., Xu, B., van Kempen, L. C. & Spatz, A. The dual role of the X-linked FoxP3 gene in human cancers. Mol. Oncol. 5, 156\u2013163 (2011).","journal-title":"Mol. Oncol."},{"key":"3554_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ccr.2009.08.016","volume":"16","author":"L Wang","year":"2009","unstructured":"Wang, L. et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16, 336\u2013346 (2009).","journal-title":"Cancer Cell"},{"key":"3554_CR23","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-10-3268","volume":"71","author":"W Li","year":"2011","unstructured":"Li, W. et al. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res. 71, 2162\u20132171 (2011).","journal-title":"Cancer Res."},{"key":"3554_CR24","first-page":"3765","volume":"117","author":"T Zuo","year":"2007","unstructured":"Zuo, T. et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Investig. 117, 3765\u20133773 (2007).","journal-title":"J. Clin. Investig."},{"key":"3554_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","volume":"129","author":"T Zuo","year":"2007","unstructured":"Zuo, T. et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene. Cell 129, 1275\u20131286 (2007).","journal-title":"Cell"},{"key":"3554_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0700-1","volume":"16","author":"S Yang","year":"2017","unstructured":"Yang, S. et al. FOXP3 promotes tumor growth and metastasis by activating Wnt\/beta-catenin signaling pathway and EMT in non-small cell lung cancer. Mol. Cancer 16, 124 (2017).","journal-title":"Mol. Cancer"},{"key":"3554_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2009.06.001","volume":"287","author":"HY Zhang","year":"2010","unstructured":"Zhang, H. Y. & Sun, H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 287, 91\u201397 (2010).","journal-title":"Cancer Lett."},{"key":"3554_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole, R. & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16, 203\u2013222 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3554_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrg.2016.134","volume":"17","author":"CP Bracken","year":"2016","unstructured":"Bracken, C. P., Scott, H. S. & Goodall, G. J. A network-biology perspective of microRNA function and dysfunction in cancer. Nat. Rev. Genet. 17, 719\u2013732 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"3554_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrc3932","volume":"15","author":"S Lin","year":"2015","unstructured":"Lin, S. & Gregory, R. I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15, 321\u2013333 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"3554_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","volume":"9","author":"G Di Leva","year":"2014","unstructured":"Di Leva, G., Garofalo, M. & Croce, C. M. MicroRNAs in cancer. Annu. Rev. Pathol. 9, 287\u2013314 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"3554_CR32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41388-019-1025-x","volume":"39","author":"CH Tung","year":"2020","unstructured":"Tung, C. H. et al. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer. Oncogene 39, 862\u2013876 (2020).","journal-title":"Oncogene"},{"key":"3554_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep39001","volume":"6","author":"H Li","year":"2016","unstructured":"Li, H. et al. MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4. Sci. Rep. 6, 39001 (2016).","journal-title":"Sci. Rep."},{"key":"3554_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080707","volume":"8","author":"S Huang","year":"2013","unstructured":"Huang, S. et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS ONE 8, e80707 (2013).","journal-title":"PLoS ONE"},{"key":"3554_CR35","first-page":"747","volume":"40","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int. J. Oncol. 40, 747\u2013756 (2012).","journal-title":"Int. J. Oncol."},{"key":"3554_CR36","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/jcmm.12398","volume":"18","author":"J Feng","year":"2014","unstructured":"Feng, J. et al. miR-150 functions as a tumour suppressor in human colorectal cancer by targeting c-Myb. J. Cell. Mol. Med. 18, 2125\u20132134 (2014).","journal-title":"J. Cell. Mol. Med."},{"key":"3554_CR37","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.2147\/OTT.S161996","volume":"11","author":"W Tang","year":"2018","unstructured":"Tang, W. et al. MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2. Onco Targets Ther. 11, 2319\u20132332 (2018).","journal-title":"Onco Targets Ther."},{"key":"3554_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.omtn.2019.04.017","volume":"16","author":"FQ Dai","year":"2019","unstructured":"Dai, F. Q. et al. miR-150-5p inhibits non-small-cell lung cancer metastasis and recurrence by targeting HMGA2 and beta-catenin signaling. Mol. Ther. Nucleic Acids 16, 675\u2013685 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"3554_CR39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41419-019-1604-3","volume":"10","author":"Z Huang","year":"2019","unstructured":"Huang, Z. et al. miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. Cell Death Dis. 10, 372 (2019).","journal-title":"Cell Death Dis."},{"key":"3554_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13046-019-1263-3","volume":"38","author":"K Luo","year":"2019","unstructured":"Luo, K. et al. LncRNA CASC9 interacts with CPSF3 to regulate TGF-beta signaling in colorectal cancer. J. Exp. Clin. Cancer Res. 38, 249 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"3554_CR41","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1021\/pr400273z","volume":"12","author":"HC Lin","year":"2013","unstructured":"Lin, H. C. et al. Quantitative proteomic analysis identifies CPNE3 as a novel metastasis-promoting gene in NSCLC. J. Proteome Res. 12, 3423\u20133433 (2013).","journal-title":"J. Proteome Res."},{"key":"3554_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/carcin\/bgr304","volume":"33","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis 33, 519\u2013528 (2012).","journal-title":"Carcinogenesis"},{"key":"3554_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06434-4","volume":"9","author":"A Yokoi","year":"2018","unstructured":"Yokoi, A. et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun. 9, 4319 (2018).","journal-title":"Nat. Commun."},{"key":"3554_CR44","doi-asserted-by":"publisher","first-page":"10816","DOI":"10.18632\/oncotarget.2522","volume":"5","author":"R Dong","year":"2014","unstructured":"Dong, R. et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 5, 10816\u201310829 (2014).","journal-title":"Oncotarget"},{"key":"3554_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27521-y","volume":"8","author":"A Nagy","year":"2018","unstructured":"Nagy, A., Lanczky, A., Menyhart, O. & Gyorffy, B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8, 9227 (2018).","journal-title":"Sci. Rep."},{"key":"3554_CR46","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"3554_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2019.04.030","volume":"456","author":"APN Rodrigues Alves","year":"2019","unstructured":"Rodrigues Alves, A. P. N. et al. IGF1R\/IRS1 targeting has cytotoxic activity and inhibits PI3K\/AKT\/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Lett. 456, 59\u201368 (2019).","journal-title":"Cancer Lett."},{"key":"3554_CR48","doi-asserted-by":"publisher","first-page":"D87","DOI":"10.1093\/nar\/gkaa516","volume":"48","author":"O Fornes","year":"2020","unstructured":"Fornes, O. et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48, D87\u2013D92 (2020).","journal-title":"Nucleic Acids Res."},{"key":"3554_CR49","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1084\/jem.20101156","volume":"207","author":"M Merkenschlager","year":"2010","unstructured":"Merkenschlager, M. & von Boehmer, H. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J. Exp. Med. 207, 1347\u20131350 (2010).","journal-title":"J. Exp. Med."},{"key":"3554_CR50","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.1073\/pnas.0800928105","volume":"105","author":"S Sauer","year":"2008","unstructured":"Sauer, S. et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl Acad. Sci. USA 105, 7797\u20137802 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3554_CR51","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2007.07.021","volume":"131","author":"C Xiao","year":"2007","unstructured":"Xiao, C. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146\u2013159 (2007).","journal-title":"Cell"},{"key":"3554_CR52","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1084\/jem.20111386","volume":"208","author":"NA Bezman","year":"2011","unstructured":"Bezman, N. A., Chakraborty, T., Bender, T. & Lanier, L. L. miR-150 regulates the development of NK and iNKT cells. J. Exp. Med. 208, 2717\u20132731 (2011).","journal-title":"J. Exp. Med."},{"key":"3554_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.molcel.2010.06.010","volume":"39","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y. et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 39, 133\u2013144 (2010).","journal-title":"Mol. Cell"},{"key":"3554_CR54","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.ejca.2013.12.024","volume":"50","author":"M Cao","year":"2014","unstructured":"Cao, M. et al. miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur. J. Cancer 50, 1013\u20131024 (2014).","journal-title":"Eur. J. Cancer"},{"key":"3554_CR55","doi-asserted-by":"crossref","unstructured":"Tan Z., Jia J., Jiang Y. MiR-150-3p targets SP1 and suppresses the growth of glioma cells. Biosci. Rep. 38, 3 (2018).","DOI":"10.1042\/BSR20180019"},{"key":"3554_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061015","volume":"8","author":"L Farhana","year":"2013","unstructured":"Farhana, L. et al. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS ONE 8, e61015 (2013).","journal-title":"PLoS ONE"},{"key":"3554_CR57","doi-asserted-by":"publisher","first-page":"72788","DOI":"10.18632\/oncotarget.20348","volume":"8","author":"TH Kim","year":"2017","unstructured":"Kim, T. H. et al. miR-150 enhances apoptotic and anti-tumor effects of paclitaxel in paclitaxel-resistant ovarian cancer cells by targeting Notch3. Oncotarget 8, 72788\u201372800 (2017).","journal-title":"Oncotarget"},{"key":"3554_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103965","volume":"9","author":"M Jin","year":"2014","unstructured":"Jin, M., Yang, Z., Ye, W., Xu, H. & Hua, X. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS ONE 9, e103965 (2014).","journal-title":"PLoS ONE"},{"key":"3554_CR59","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/nature05563","volume":"445","author":"Y Zheng","year":"2007","unstructured":"Zheng, Y. et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445, 936\u2013940 (2007).","journal-title":"Nature"},{"key":"3554_CR60","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu, L., Barbi, J. & Pan, F. The regulation of immune tolerance by FOXP3. Nat. Rev. Immunol. 17, 703\u2013717 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"3554_CR61","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/ni.2402","volume":"13","author":"D Rudra","year":"2012","unstructured":"Rudra, D. et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13, 1010\u20131019 (2012).","journal-title":"Nat. Immunol."},{"key":"3554_CR62","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538\u201318543 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3554_CR63","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-13-3448","volume":"20","author":"PJ Beltran","year":"2014","unstructured":"Beltran, P. J. et al. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin. Cancer Res. 20, 2947\u20132958 (2014).","journal-title":"Clin. Cancer Res."},{"key":"3554_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-71","volume":"6","author":"J Tang","year":"2013","unstructured":"Tang, J. et al. Antisense oligonucleotide suppression of human IGF-1R inhibits the growth and survival of in vitro cultured epithelial ovarian cancer cells. J. Ovarian Res. 6, 71 (2013).","journal-title":"J. Ovarian Res."},{"key":"3554_CR65","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/bjc.2014.497","volume":"111","author":"I Brana","year":"2014","unstructured":"Brana, I. et al. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br. J. Cancer 111, 1932\u20131944 (2014).","journal-title":"Br. J. Cancer"},{"key":"3554_CR66","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nrd3992","volume":"12","author":"M Guha","year":"2013","unstructured":"Guha, M. Anticancer IGF1R classes take more knocks. Nat. Rev. Drug Discov. 12, 250 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3554_CR67","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3215","volume":"12","author":"M Pollak","year":"2012","unstructured":"Pollak, M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 12, 159\u2013169 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"3554_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjd.12913","volume":"171","author":"YY Wang","year":"2014","unstructured":"Wang, Y. Y. et al. DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br. J. Dermatol. 171, 39\u201347 (2014).","journal-title":"Br. J. Dermatol."},{"key":"3554_CR69","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.4049\/jimmunol.1502352","volume":"196","author":"V Sasidharan Nair","year":"2016","unstructured":"Sasidharan Nair, V., Song, M. H. & Oh, K. I. Vitamin C facilitates demethylation of the Foxp3 enhancer in a Tet-dependent manner. J. Immunol. 196, 2119\u20132131 (2016).","journal-title":"J. Immunol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03554-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:37:27Z","timestamp":1669901847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-03554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["3554"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-03554-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"275"}}